Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Fineline Cube Jan 4, 2026
Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Policy / Regulatory

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support

Fineline Cube Jan 4, 2026
Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026
Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Fineline Cube Jan 4, 2026
Company Drug

Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First‑In‑Class Glucokinase Activator

Fineline Cube Sep 29, 2025

China‑based Hua Medicine (HKG: 2552) announced that the Hong Kong Department of Health has accepted its...

Company Drug

Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211

Fineline Cube Sep 29, 2025

Shandong Xinhua Pharmaceutical Co., Ltd. (HKG: 0719) announced that its pulmonary arterial hypertension (PAH) candidate...

Company Drug

Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria

Fineline Cube Sep 29, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) announced that the National Medical Products Administration...

Company Drug

Eisai & Biogen Secure Leqembi China Maintenance Approval

Fineline Cube Sep 29, 2025

Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced...

Company Drug

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...

Company Deals Drug

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

Fineline Cube Sep 29, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd., a leading Chinese cancer‑immunotherapy firm, announced an exclusive licensing...

Company Drug

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Fineline Cube Sep 28, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...

Company

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Fineline Cube Sep 28, 2025

Merck KGaA (ETR: MRK) announced that Kai Beckmann will assume the roles of Chair of...

Policy / Regulatory

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says

Fineline Cube Sep 28, 2025

A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...

Company Digital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Fineline Cube Sep 28, 2025

Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A—the world’s first B7H3‑targeted, off‑the‑shelf allogeneic...

Company Deals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Fineline Cube Sep 28, 2025

Wolters Kluwer announced a preliminary collaboration agreement with the Institute of Medical Information of the...

Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Fineline Cube Sep 28, 2025

Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...

Company Deals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

Fineline Cube Sep 28, 2025

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) and Nanjing ProBio, a subsidiary of GenScript Biotech...

Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...

Company Drug

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Fineline Cube Sep 26, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Fineline Cube Sep 26, 2025

President Donald J. Trump announced via a social‑media post that the United States will impose a 100 % tariff...

Policy / Regulatory

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) released the National Long‑Term Care Insurance Service Catalog (Trial),...

Company Drug

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma

Fineline Cube Sep 26, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug...

Company Drug Policy / Regulatory

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot

Fineline Cube Sep 26, 2025

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that...

Posts pagination

1 … 35 36 37 … 603

Recent updates

  • Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
  • China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
  • China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
  • Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
  • Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.